Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Despite global efforts to decrease discomfort during surgical abortion, pain remains a limiting factor in where and how procedures are performed. Several studies have investigated different methods of delivering cervical anesthesia prior to abortion, however to the best of the investigators' knowledge, there is no published data that 1) rigorously examines the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explores whether adequate pain relief is possible through self-administered, non-invasive means alone. Research in this area has a significant public health impact, given the large number of women worldwide who seek abortions.
The investigators propose to explore the effect of a locally applied vaginal lidocaine gel in place of the traditional paracervical block prior to first trimester surgical abortion. They hypothesize that lidocaine gel is no worse than paracervical block at decreasing abortion related pain at a variety of time points throughout the procedure. This is a non-inferiority, open label, randomized controlled trial.
If self-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures.
Abortion remains one of the most common surgical procedures in the world, regardless of region or development status [Guttmacher 2012]. In the United States, at least half of all women will experience an unintended pregnancy by age 45, and one third of all women will have had an abortion by this same age [Guttmacher 2014].
Despite universal efforts to increase the comfort of these procedures, pain remains a limiting factor in where and how abortion is performed. Recent estimates reveal that 70-97% of women experience pain during abortion [Renner 2010, Paul 2009, Belanger 1988]. Strategies to reduce all aspects of abortion related pain have the potential for significant public health impact, given the large number of women who seek these services. A survey of National Abortion Federation clinics found that to date, most providers (84%) employ the use of a lidocaine paracervical block for cervical anesthesia prior to abortion [O'Connell 2009], but traditionally without a waiting period between lidocaine administration and procedure initiation.
To the best of our knowledge, there are no published studies that 1) rigorously examine the effect of a time interval between local anesthetic administration and procedure initiation, or 2) explore whether adequate pain relief is possible through self-administered, non-invasive means alone. The investigators propose to explore the effect of a locally applied lidocaine gel in place of the traditional paracervical block to decrease abortion related pain.
The objective of this study is to compare pain control at various time points during first trimester surgical abortion using a locally applied, patient-administered lidocaine gel as compared to traditional lidocaine paracervical block.
If a patient-administered vaginal gel is acceptable and effective, it would increase options for pain control during abortion and other gynecologic procedures, and perhaps replace paracervical injection altogether.
Hypothesis: Patients who receive lidocaine gel applied 30 minutes prior to first trimester surgical abortion will have pain control equivalent to that of a traditional paracervical block.
This is a non-inferiority, open-label, randomized controlled trial of women ages 18 and older undergoing first trimester surgical abortion at 50/7 to 116/7 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Comparator | Experimental | Drug: vaginal 2% Xylocaine |
|
| standard lidocaine paracervical block | Other | standard lidocaine paracervical block |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vaginal 2% Xylocaine | Drug | patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient at the time of cervical dilation. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | At time of cervical dilation, 30 minutes after lidocaine administration |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient prior to the procedure (Anticipated pain). VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Pain level prior to procedure |
| Pain With Speculum Insertion as Measured by a Visual Analog Scale |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Planned Parenthood Mar Monte | San Jose | California | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27400015 | Derived | Conti JA, Lerma K, Shaw KA, Blumenthal PD. Self-Administered Lidocaine Gel for Pain Control With First-Trimester Surgical Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2016 Aug;128(2):297-303. doi: 10.1097/AOG.0000000000001532. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Active Comparator | Drug: vaginal 2% Xylocaine vaginal 2% Xylocaine: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block |
| FG001 | Standard Lidocaine Paracervical Block | standard lidocaine paracervical block standard lidocaine paracervical block: 1% lidocaine paracervical injection |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Treated participants were analyzed for baseline characteristics.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active Comparator | Drug: vaginal 2% Xylocaine vaginal 2% Xylocaine: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block |
| BG001 | Standard Lidocaine Paracervical Block |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Difference in Pain Level at Time of Cervical Dilation as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient at the time of cervical dilation. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Treated participants were included in the analysis. | Posted | Median | Inter-Quartile Range | units on a scale | At time of cervical dilation, 30 minutes after lidocaine administration |
|
Not provided
Treated participants were included in the analysis.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Active Comparator | Drug: vaginal 2% Xylocaine vaginal 2% Xylocaine: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Principal Investigator | Stanford University | 650-497-5175 | gynresearch@stanford.edu |
Not provided
| ID | Term |
|---|---|
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008012 | Lidocaine |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| standard lidocaine paracervical block | Drug | 1% lidocaine paracervical injection |
|
This is the amount of pain self-reported by the patient at the time of speculum insertion. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. |
| Pain at time of speculum insertion |
| Pain With Tenaculum Placement as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient at the time of tenaculum placement. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Pain at time of tenaculum placement |
| Pain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient 30-45 minutes after procedure. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Pain prior to discharge home: 30-45 minutes after completion of procedure |
| Overall Satisfaction With Procedure as Measured by a Visual Analog Scale | This is the level of overall satisfaction self-reported by the patient at the completion of the procedure and prior to discharge. VAS ranged from 0 to 100 mm, 0 equals not satisfied, 100 equals highest satisfaction possible. | 30-45 minutes after completion of procedure |
| Overall Complication Rate as Measured by a Count of Participants in Each Group | Rate of complications at the end of the study |
standard lidocaine paracervical block
standard lidocaine paracervical block: 1% lidocaine paracervical injection
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
standard lidocaine paracervical block
standard lidocaine paracervical block: 1% lidocaine paracervical injection
|
|
| Secondary | Pain Level Prior to Procedure (Anticipated Pain) as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient prior to the procedure (Anticipated pain). VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Treated patients were included in the analysis | Posted | Median | Inter-Quartile Range | units on a scale | Pain level prior to procedure |
|
|
|
| Secondary | Pain With Speculum Insertion as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient at the time of speculum insertion. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | Treated patients were included in the analysis | Posted | Mean | Standard Deviation | units on a scale | Pain at time of speculum insertion |
|
|
|
| Secondary | Pain With Tenaculum Placement as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient at the time of tenaculum placement. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | All treated patients were included in the analysis | Posted | Mean | Standard Deviation | units on a scale | Pain at time of tenaculum placement |
|
|
|
| Secondary | Pain 30-45 Minutes After Procedure as Measured by a Visual Analog Scale | This is the amount of pain self-reported by the patient 30-45 minutes after procedure. VAS ranged from 0 to 100 mm, 0 equals no pain, 100 equals worse pain imaginable. | All treated patients were included in the analysis | Posted | Median | Inter-Quartile Range | units on a scale | Pain prior to discharge home: 30-45 minutes after completion of procedure |
|
|
|
| Secondary | Overall Satisfaction With Procedure as Measured by a Visual Analog Scale | This is the level of overall satisfaction self-reported by the patient at the completion of the procedure and prior to discharge. VAS ranged from 0 to 100 mm, 0 equals not satisfied, 100 equals highest satisfaction possible. | All treated patients were included in the analysis | Posted | Median | Inter-Quartile Range | units on a scale | 30-45 minutes after completion of procedure |
|
|
|
| Secondary | Overall Complication Rate as Measured by a Count of Participants in Each Group | All treated patients were analyzed | Posted | Count of Participants | Participants | Rate of complications at the end of the study |
|
|
|
| 0 |
| 69 |
| 0 |
| 69 |
| EG001 | Standard Lidocaine Paracervical Block | standard lidocaine paracervical block standard lidocaine paracervical block: 1% lidocaine paracervical injection | 0 | 68 | 0 | 68 |
Not provided
Not provided
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Aniline Compounds |
| D000588 | Amines |